Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above 200-Day Moving Average of $1.40

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.40 and traded as high as $1.75. Spero Therapeutics shares last traded at $1.71, with a volume of 96,259 shares changing hands.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Thursday, April 4th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Spero Therapeutics in a research note on Monday, March 18th.

Spero Therapeutics Trading Up 0.6 %

The business’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.40. The firm has a market cap of $92.12 million, a P/E ratio of 4.07 and a beta of 0.55.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Wednesday, March 13th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $1.14. The business had revenue of $73.52 million for the quarter, compared to analysts’ expectations of $19.40 million. Spero Therapeutics had a net margin of 21.98% and a return on equity of 38.54%. As a group, research analysts expect that Spero Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its holdings in shares of Spero Therapeutics by 132.0% in the first quarter. Bank of America Corp DE now owns 18,417 shares of the company’s stock worth $27,000 after purchasing an additional 10,479 shares during the period. Engineers Gate Manager LP bought a new position in shares of Spero Therapeutics in the first quarter worth $95,000. XTX Topco Ltd bought a new position in shares of Spero Therapeutics in the first quarter worth $115,000. Royal Bank of Canada increased its holdings in shares of Spero Therapeutics by 7.4% in the first quarter. Royal Bank of Canada now owns 196,097 shares of the company’s stock worth $1,706,000 after purchasing an additional 13,502 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Spero Therapeutics in the third quarter worth $31,000. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.